Results 21 to 30 of about 5,337 (191)

Aducanumab for alzheimer's disease:An update [PDF]

, 2021
The US FDA approved Aducanumab in June 2021 as the first Alzheimer's disease (AD) drug under its accelerated approval pathway. It has given some hope to patients suffering from AD around the world.
Shaikh, Mohd Farooq, Retinasamy, Thaarvena   +1 more
core   +1 more source

ADUCANUMAB NO TRATAMENTO DA DOENÇA DE ALZHEIMER [PDF]

, 2023
Introduction: Alzheimer\u27s disease (AD) is a chronic pathology, characterized by progressive cognitive impairment and neurobehavioral changes. Common treatments for Alzheimer\u27s disease are symptomatic in focus and have modest benefits.
Miguel Neri Beraldo da Silva, Jorge Henrique De Souza Almeida, Nakano Pereira, Pedro, Ana Flávia Fonseca de Oliveira, Tochihide Iamaguti, Felipe, de Oliveira Ferreira, Igor Henrique, Fonseca de Oliveira, Ana Flávia, ´Peruzzi Iamaguti, Júlia, Mendonça Rocha, Carollayne, Alexandre Teixeira do Amaral, de Souza Almeida, Jorge Henrique, Azara Oliveira, Eric, Júlia ´Peruzzi Iamaguti, Felipe Tochihide Iamaguti, Igor Henrique De Oliveira Ferreira, Pedro Nakano Pereira, Eric Azara Oliveira, Carollayne Mendonça Rocha, Teixeira do Amaral, Alexandre, Neri Beraldo da Silva, Miguel   +19 more
core   +1 more source

“Real world” eligibility for aducanumab [PDF]

Journal of the American Geriatrics Society, 2021
n ...
Canevelli, Marco, Rossi, Paolo Dionigi, Astrone, Paolo, Consorti, Ernesto, Vanacore, Nicola, Cesari, Matteo   +5 more
openaire   +4 more sources

Aducanumab

Reactions Weekly
Introduction and Definition: Aducanumab is “a human monoclonal antibody that selectively targets aggregated Aβ [amyloid-beta protein]”. This has been used as a novel therapy for treating Alzheimer’s disease (AD), as AD is characterized by an accumulation of amyloid plaques in the brain, which are proposed to lead to the cognitive decline attributed to ...
Padda IS, Preuss CV, Parmar M.
europepmc   +5 more sources

An insider's perspective on FDA approval of aducanumab

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2023
Introduction Aducanumab was approved in 2021 by the US Food and Drug Administration (FDA) under the accelerated approval pathway. Since then, there have been many misconceptions about the approval decision despite multiple publications from the FDA to ...
Yaning Wang
doaj   +1 more source

Aducanumab: A new hope in Alzheimer's disease

Health Sciences Review, 2022
Alzheimer's disease is an insidious, slowly progressive neurodegenerative disease in aged people and the most prevalent form of dementia, characterized by loss of memory, behavioral changes, cognitive deterioration, and loss of functional abilities that ...
Rouchan Ali, Ghanshyam Das Gupta, Pooja A. Chawla   +2 more
doaj   +1 more source

Aducanumab: evidence from clinical trial data and controversies

Drugs in Context, 2021
Alzheimer’s disease (AD) is the most common cause for dementia worldwide. Until recently, all approved treatments for AD were symptomatic and not disease modifying.
Rajesh R Tampi, Brent P Forester, Marc Agronin   +2 more
doaj   +1 more source

Of education and public policy: Aducanumab [PDF]

Journal of the American Geriatrics Society, 2021
See related letter by Padovani et al .
Nancy E, Lundebjerg, Peter A, Hollmann, Mark A, Supiano   +2 more
openaire   +2 more sources

Alzheimer’s disease: the controversial approval of Aducanumab [PDF]

Neurological Sciences, 2021
n ...
Tagliavini, Fabrizio, Tiraboschi, Pietro, Federico, Antonio   +2 more
openaire   +2 more sources

Aducanumab: an uprising hope with vague horizons

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2023
Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Amyloid-beta (Aβ) deposition, is one of the processes involved in the pathophysiology of AD, has inspired interest in targeted therapies, including monoclonal antibodies.
Delara Hazegh Fetratjoo, Alireza Kargar, Maryam Noroozian   +2 more
doaj   +1 more source